Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2011

Goodwill and Other Intangible Assets [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

Goodwill and Other Intangible Assets

As part of the Company’s annual impairment review as of December 31, 2010, a $0.6 million goodwill impairment charge was recorded due to lower than expected revenue and operating income growth of its adult stem cell banking area. The Company estimated the fair value utilizing a discounted cash flow model.

The changes in the carrying amount of goodwill during 2011 and 2010 were as follows (in thousands):



	Total
Balance as of December 31, 2009	$	558.2
Impairment	(558.2		)
Balance as of December 31, 2010	—
Acquisitions*	11,117.8
Balance as of December 31, 2011	$	11,117.8

* Approximately $7.0 million associated with the PCT Merger, and $4.1 million associated with Amorcyte merger

As of December 31, 2011 and 2010, the Company’s intangible assets and related accumulated amortization consisted of the following (in thousands):



		12/31/2011				12/31/2010
	Useful Life	Gross	Accumulated Amortization		Net	Gross	Accumulated Amortization		Net
Customer list	10 Years	1,000.0	(95.1	)	904.9	—	—		—
Manufacturing technology	10 Years	3,900.0	(370.9	)	3,529.1	—	—		—
Tradename	10 Years	800.0	(76.2	)	723.8	—	—		—
In process R&D	Indefinite	9,400.0	—		9,400.0	—	—		—
VSEL patent rights	19 Years	669.0	(140.8	)	528.2	669.0	(105.6	)	563.4
Total Intangible Assets		15,769.0	(683.0	)	15,086.0	669.0	(105.6	)	563.4

In connection with the acquisition of PCT, the following intangible assets were acquired (in thousands):




Customer list	$	1,000.0
Manufacturing technology	3,900.0
Tradename	800.0
Intangible Assets, PCT Acquisition	$	5,700.0

In connection with the acquisition of Amorcyte, an In Process R&D intangible asset of $9,400,000 was recorded.

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Years Ended December 31,
	2011		2010
Cost of revenue	$	370.9	$	—
Research and development	35.2		35.2
Selling, general and administrative	171.2		—
Total	$	577.3	$	35.2

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follows (in thousands):




2012	$	605.2
2013	605.2
2014	605.2
2015	605.2
2016	605.2
Thereafter	12,060.0
	$	15,086.0

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details